APO Research
Talk to an analyst

APO RESEARCH · REPORT

Atrophic Vaginitis Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Atrophic Vaginitis Treatment Market Outlook and Growth Opportunities 2026

21 December 2025190 pages

Choose your research edition.

Industry ResearchAtrophic Vaginitis Treatment Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Atrophic Vaginitis Treatment Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Atrophic Vaginitis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Atrophic Vaginitis Treatment Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Atrophic Vaginitis Treatment Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Atrophic Vaginitis Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Atrophic Vaginitis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Atrophic Vaginitis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Atrophic Vaginitis Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Atrophic Vaginitis Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Atrophic Vaginitis Treatment market include Bayer HealthCare Pharmaceuticals Inc, Theramex, Shionogi, Pantarhei Bioscience, Mithra Pharmaceuticals, Hormos Medical, Endoceutics, Duchesnay and AMAG Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Atrophic Vaginitis Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Atrophic Vaginitis Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Atrophic Vaginitis Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Atrophic Vaginitis Treatment market.

Atrophic Vaginitis Treatment Segment by Company

Bayer HealthCare Pharmaceuticals Inc

Theramex

Shionogi

Pantarhei Bioscience

Mithra Pharmaceuticals

Hormos Medical

Endoceutics

Duchesnay

AMAG Pharmaceuticals

Atrophic Vaginitis Treatment Segment by Type

Vaginal Moisturizers

Water-based Lubricants

Atrophic Vaginitis Treatment Segment by Application

Retail Pharmacy

Online Pharmacy

Hospital Pharmacy

Atrophic Vaginitis Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Atrophic Vaginitis Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Atrophic Vaginitis Treatment key companies, revenue, market share, and recent developments.

3. To split the Atrophic Vaginitis Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Atrophic Vaginitis Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Atrophic Vaginitis Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Atrophic Vaginitis Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Atrophic Vaginitis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Atrophic Vaginitis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Atrophic Vaginitis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Atrophic Vaginitis Treatment industry.

Chapter 3: Detailed analysis of Atrophic Vaginitis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Atrophic Vaginitis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Atrophic Vaginitis Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Atrophic Vaginitis Treatment Industry Trends Table 2. Atrophic Vaginitis Treatment Industry Drivers Table 3. Atrophic Vaginitis Treatment Industry Opportunities and Challenges Table 4. Atrophic Vaginitis Treatment Industry Restraints Table 5. Global Atrophic Vaginitis Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Atrophic Vaginitis Treatment Revenue Share by Company (2021-2026) Table 7. Global Atrophic Vaginitis Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Atrophic Vaginitis Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Atrophic Vaginitis Treatment Company, Product Type & Application Table 10. Global Atrophic Vaginitis Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Atrophic Vaginitis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Vaginal Moisturizers Table 15. Significant Companies of Water-based Lubricants Table 16. Global Atrophic Vaginitis Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Atrophic Vaginitis Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Atrophic Vaginitis Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Atrophic Vaginitis Treatment Sales Value Share by Type (2021-2026) Table 20. Global Atrophic Vaginitis Treatment Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Retail Pharmacy Table 22. Significant Companies of Online Pharmacy Table 23. Significant Companies of Hospital Pharmacy Table 24. Global Atrophic Vaginitis Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Atrophic Vaginitis Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Atrophic Vaginitis Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Atrophic Vaginitis Treatment Sales Value Share by Application (2021-2026) Table 28. Global Atrophic Vaginitis Treatment Sales Value Share by Application (2027-2032) Table 29. Global Atrophic Vaginitis Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Atrophic Vaginitis Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Atrophic Vaginitis Treatment Sales Value Share by Region (2021-2026) Table 32. Global Atrophic Vaginitis Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Atrophic Vaginitis Treatment Sales Value Share by Region (2027-2032) Table 34. Global Atrophic Vaginitis Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Atrophic Vaginitis Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Atrophic Vaginitis Treatment Sales Value Market Share by Country (2021-2026) Table 37. Global Atrophic Vaginitis Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Atrophic Vaginitis Treatment Sales Value Market Share by Country (2027-2032) Table 39. Bayer HealthCare Pharmaceuticals Inc Company Information Table 40. Bayer HealthCare Pharmaceuticals Inc Business Overview Table 41. Bayer HealthCare Pharmaceuticals Inc Atrophic Vaginitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Bayer HealthCare Pharmaceuticals Inc Atrophic Vaginitis Treatment Product Portfolio Table 43. Bayer HealthCare Pharmaceuticals Inc Recent Development Table 44. Theramex Company Information Table 45. Theramex Business Overview Table 46. Theramex Atrophic Vaginitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Theramex Atrophic Vaginitis Treatment Product Portfolio Table 48. Theramex Recent Development Table 49. Shionogi Company Information Table 50. Shionogi Business Overview Table 51. Shionogi Atrophic Vaginitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Shionogi Atrophic Vaginitis Treatment Product Portfolio Table 53. Shionogi Recent Development Table 54. Pantarhei Bioscience Company Information Table 55. Pantarhei Bioscience Business Overview Table 56. Pantarhei Bioscience Atrophic Vaginitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Pantarhei Bioscience Atrophic Vaginitis Treatment Product Portfolio Table 58. Pantarhei Bioscience Recent Development Table 59. Mithra Pharmaceuticals Company Information Table 60. Mithra Pharmaceuticals Business Overview Table 61. Mithra Pharmaceuticals Atrophic Vaginitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Mithra Pharmaceuticals Atrophic Vaginitis Treatment Product Portfolio Table 63. Mithra Pharmaceuticals Recent Development Table 64. Hormos Medical Company Information Table 65. Hormos Medical Business Overview Table 66. Hormos Medical Atrophic Vaginitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Hormos Medical Atrophic Vaginitis Treatment Product Portfolio Table 68. Hormos Medical Recent Development Table 69. Endoceutics Company Information Table 70. Endoceutics Business Overview Table 71. Endoceutics Atrophic Vaginitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Endoceutics Atrophic Vaginitis Treatment Product Portfolio Table 73. Endoceutics Recent Development Table 74. Duchesnay Company Information Table 75. Duchesnay Business Overview Table 76. Duchesnay Atrophic Vaginitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Duchesnay Atrophic Vaginitis Treatment Product Portfolio Table 78. Duchesnay Recent Development Table 79. AMAG Pharmaceuticals Company Information Table 80. AMAG Pharmaceuticals Business Overview Table 81. AMAG Pharmaceuticals Atrophic Vaginitis Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. AMAG Pharmaceuticals Atrophic Vaginitis Treatment Product Portfolio Table 83. AMAG Pharmaceuticals Recent Development Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. Atrophic Vaginitis Treatment Product Image Figure 2. Global Atrophic Vaginitis Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Atrophic Vaginitis Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Atrophic Vaginitis Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Vaginal Moisturizers Image Figure 8. Water-based Lubricants Image Figure 9. Global Atrophic Vaginitis Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Atrophic Vaginitis Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Atrophic Vaginitis Treatment Sales Value Share by Type (2021-2032) Figure 12. Retail Pharmacy Image Figure 13. Online Pharmacy Image Figure 14. Hospital Pharmacy Image Figure 15. Global Atrophic Vaginitis Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Atrophic Vaginitis Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Atrophic Vaginitis Treatment Sales Value Share by Application (2021-2032) Figure 18. Global Atrophic Vaginitis Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Atrophic Vaginitis Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Atrophic Vaginitis Treatment Sales Value (2021-2032) & (US$ Million) Figure 21. North America Atrophic Vaginitis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Atrophic Vaginitis Treatment Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Atrophic Vaginitis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Atrophic Vaginitis Treatment Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Atrophic Vaginitis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Atrophic Vaginitis Treatment Sales Value (2021-2032) & (US$ Million) Figure 27. South America Atrophic Vaginitis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Atrophic Vaginitis Treatment Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Atrophic Vaginitis Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Vaginal Moisturizers
  • Water-based Lubricants
Applications
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
Companies covered
  • Bayer HealthCare Pharmaceuticals Inc
  • Theramex
  • Shionogi
  • Pantarhei Bioscience
  • Mithra Pharmaceuticals
  • Hormos Medical
  • Endoceutics
  • Duchesnay
  • AMAG Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Atrophic Vaginitis Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Atrophic Vaginitis Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Atrophic Vaginitis Treatment Market Dynamics
  1. 2.1 Atrophic Vaginitis Treatment Industry Trends
  2. 2.2 Atrophic Vaginitis Treatment Industry Drivers
  3. 2.3 Atrophic Vaginitis Treatment Industry Opportunities and Challenges
  4. 2.4 Atrophic Vaginitis Treatment Industry Restraints
3 Atrophic Vaginitis Treatment Market by Company
  1. 3.1 Global Atrophic Vaginitis Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Atrophic Vaginitis Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Atrophic Vaginitis Treatment Company Ranking (2024-2026)
  4. 3.4 Global Atrophic Vaginitis Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Atrophic Vaginitis Treatment Company Product Type and Application
  6. 3.6 Global Atrophic Vaginitis Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Atrophic Vaginitis Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Atrophic Vaginitis Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Atrophic Vaginitis Treatment Market by Type
  1. 4.1 Atrophic Vaginitis Treatment Type Introduction
  2. 4.1.1 Vaginal Moisturizers
  3. 4.1.2 Water-based Lubricants
  4. 4.2 Global Atrophic Vaginitis Treatment Sales Value by Type
  5. 4.2.1 Global Atrophic Vaginitis Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Atrophic Vaginitis Treatment Sales Value by Type (2021-2032)
  7. 4.2.3 Global Atrophic Vaginitis Treatment Sales Value Share by Type (2021-2032)
5 Atrophic Vaginitis Treatment Market by Application
  1. 5.1 Atrophic Vaginitis Treatment Application Introduction
  2. 5.1.1 Retail Pharmacy
  3. 5.1.2 Online Pharmacy
  4. 5.1.3 Hospital Pharmacy
  5. 5.2 Global Atrophic Vaginitis Treatment Sales Value by Application
  6. 5.2.1 Global Atrophic Vaginitis Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Atrophic Vaginitis Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Atrophic Vaginitis Treatment Sales Value Share by Application (2021-2032)
6 Atrophic Vaginitis Treatment Regional Value Analysis
  1. 6.1 Global Atrophic Vaginitis Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Atrophic Vaginitis Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Atrophic Vaginitis Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Atrophic Vaginitis Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Atrophic Vaginitis Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Atrophic Vaginitis Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Atrophic Vaginitis Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Atrophic Vaginitis Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Atrophic Vaginitis Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Atrophic Vaginitis Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Atrophic Vaginitis Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Atrophic Vaginitis Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Atrophic Vaginitis Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Atrophic Vaginitis Treatment Sales Value Share by Country, 2025 VS 2032
7 Atrophic Vaginitis Treatment Country-level Value Analysis
  1. 7.1 Global Atrophic Vaginitis Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Atrophic Vaginitis Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Atrophic Vaginitis Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Atrophic Vaginitis Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Atrophic Vaginitis Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Atrophic Vaginitis Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Atrophic Vaginitis Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bayer HealthCare Pharmaceuticals Inc
  2. 8.1.1 Bayer HealthCare Pharmaceuticals Inc Company Information
  3. 8.1.2 Bayer HealthCare Pharmaceuticals Inc Business Overview
  4. 8.1.3 Bayer HealthCare Pharmaceuticals Inc Atrophic Vaginitis Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bayer HealthCare Pharmaceuticals Inc Atrophic Vaginitis Treatment Product Portfolio
  6. 8.1.5 Bayer HealthCare Pharmaceuticals Inc Recent Developments
  7. 8.2 Theramex
  8. 8.2.1 Theramex Company Information
  9. 8.2.2 Theramex Business Overview
  10. 8.2.3 Theramex Atrophic Vaginitis Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Theramex Atrophic Vaginitis Treatment Product Portfolio
  12. 8.2.5 Theramex Recent Developments
  13. 8.3 Shionogi
  14. 8.3.1 Shionogi Company Information
  15. 8.3.2 Shionogi Business Overview
  16. 8.3.3 Shionogi Atrophic Vaginitis Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shionogi Atrophic Vaginitis Treatment Product Portfolio
  18. 8.3.5 Shionogi Recent Developments
  19. 8.4 Pantarhei Bioscience
  20. 8.4.1 Pantarhei Bioscience Company Information
  21. 8.4.2 Pantarhei Bioscience Business Overview
  22. 8.4.3 Pantarhei Bioscience Atrophic Vaginitis Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pantarhei Bioscience Atrophic Vaginitis Treatment Product Portfolio
  24. 8.4.5 Pantarhei Bioscience Recent Developments
  25. 8.5 Mithra Pharmaceuticals
  26. 8.5.1 Mithra Pharmaceuticals Company Information
  27. 8.5.2 Mithra Pharmaceuticals Business Overview
  28. 8.5.3 Mithra Pharmaceuticals Atrophic Vaginitis Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mithra Pharmaceuticals Atrophic Vaginitis Treatment Product Portfolio
  30. 8.5.5 Mithra Pharmaceuticals Recent Developments
  31. 8.6 Hormos Medical
  32. 8.6.1 Hormos Medical Company Information
  33. 8.6.2 Hormos Medical Business Overview
  34. 8.6.3 Hormos Medical Atrophic Vaginitis Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hormos Medical Atrophic Vaginitis Treatment Product Portfolio
  36. 8.6.5 Hormos Medical Recent Developments
  37. 8.7 Endoceutics
  38. 8.7.1 Endoceutics Company Information
  39. 8.7.2 Endoceutics Business Overview
  40. 8.7.3 Endoceutics Atrophic Vaginitis Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Endoceutics Atrophic Vaginitis Treatment Product Portfolio
  42. 8.7.5 Endoceutics Recent Developments
  43. 8.8 Duchesnay
  44. 8.8.1 Duchesnay Company Information
  45. 8.8.2 Duchesnay Business Overview
  46. 8.8.3 Duchesnay Atrophic Vaginitis Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Duchesnay Atrophic Vaginitis Treatment Product Portfolio
  48. 8.8.5 Duchesnay Recent Developments
  49. 8.9 AMAG Pharmaceuticals
  50. 8.9.1 AMAG Pharmaceuticals Company Information
  51. 8.9.2 AMAG Pharmaceuticals Business Overview
  52. 8.9.3 AMAG Pharmaceuticals Atrophic Vaginitis Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AMAG Pharmaceuticals Atrophic Vaginitis Treatment Product Portfolio
  54. 8.9.5 AMAG Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst